NRD
CGEM icon

Nebula Research & Development’s Cullinan Oncology CGEM Stock Holding History

Nebula Research & Development’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,853
Closed -$240K – 160
2025
Q2 		$240K Sell
31,853
-11,554
-27% -$92.8K 0.02% 842
2025
Q1 		$329K Sell
43,407
-295
-0.7% -$2.83K 0.03% 734
2024
Q4 		$532K Buy
43,702
+9,165
+27% +$132K 0.06% 530
2024
Q3 		$578K Buy
34,537
+21,412
+163% +$380K 0.07% 499
2024
Q2 		$229K Sell
13,125
-11,528
-47% -$245K 0.04% 693
2024
Q1 		$420K Buy
+24,653
New +$381K 0.09% 420

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Nebula Research & Development's CGEM Position: Q3 2025 in Review

Nebula Research & Development sold out of Cullinan Oncology (CGEM) in Q3 2025, closing a stake of 31,853 shares — an estimated $240K sold.

Nebula Research & Development first reported a position in CGEM in Q1 2024 and held it in 6 quarters. The position peaked at $578K in Q3 2024. 145 funds tracked by Wall St. Rank hold CGEM as of Q3 2025.

  • Nebula Research & Development reported no remaining Cullinan Oncology position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 31,853 Cullinan Oncology shares in Q3 2025, an estimated $240K.
  • Nebula Research & Development first reported a position in Cullinan Oncology in Q1 2024 and held it in 6 quarters.
  • Nebula Research & Development's Cullinan Oncology position peaked at $578K in Q3 2024.
  • 145 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.